{"name":"AIDS Arms Inc.","slug":"aids-arms-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Kaletra soft-gel capsules switched to Kaletra tablets","genericName":"Kaletra soft-gel capsules switched to Kaletra tablets","slug":"kaletra-soft-gel-capsules-switched-to-kaletra-tablets","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Kaletra soft-gel capsules switched to Kaletra tablets","genericName":"Kaletra soft-gel capsules switched to Kaletra tablets","slug":"kaletra-soft-gel-capsules-switched-to-kaletra-tablets","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2025-07-15","type":"pipeline","source":"Business Standard","summary":"Aurobindo Pharma to manufacture, supply long acting HIV treatment drug - Business Standard","headline":"Aurobindo Pharma to manufacture, supply long acting HIV treatment drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNUDJtV0JFY1Y1S1J3RDRmY3dQQllSQXRnUXNlak1FNXBla1kwZVJNeGVaY3R1SS1TbTZZNHU0TTJNRnRQcDlEWG4xcUNwd0hvVXU5N1pQaHpIWVMwVThZZE1QOVplVXlRM20wYlV5b29oRWNQY0p6S1Bwd1AySW91MDI2QTNBNGE5aG9hYjlscmhCQ0phbXoyakxvS1NrY2tjNlcyZVp3?oc=5","date":"2024-11-27","type":"pipeline","source":"D Magazine","summary":"Meet the Dallas 500: John Carlo, Prism Health North Texas - D Magazine","headline":"Meet the Dallas 500: John Carlo, Prism Health North Texas","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9uSzRCWmVfVjdPanZOdmFHU0tWM3pkNU1uMVRHX0d2WGhmUklMTlJmTUhfQjJCbDM4MHNJM3JweVdBMmpIR2ZxcXd5eVNITFJlMm13YUtOOU1vWG9lREtF?oc=5","date":"2024-09-09","type":"trial","source":"Nature","summary":"Anti-PD-L1 antibody ASC22 in combination with a histone deacetylase inhibitor chidamide as a “shock and kill” strategy for ART-free virological control: a phase II single-arm study | Signal Transducti","headline":"Anti-PD-L1 antibody ASC22 in combination with a histone deacetylase inhibitor chidamide as a “shock and kill” strategy f","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxQdG5panFpSzhXcFlzYllHRGQ0cGkxczZkSHlMY2NoYTN2T1BGeXFwYXQxQUFWamk3X2Viby1pcGhlWGxGdnRvRlZKRjlhclk0UkUwVzBEUU0tdVNCUVI5SVlpc05DUFJrcC1lQ3dSVzUxcTh6ZkxDS2dnSEI5dk5rNlhnQjRMay1mVFYxX09yeHVGMDVscURHVEFWUC1JU0QyMmJTN1lmU1lUVm1NRUdHWEFTOXhJMnVNV2g2R2I0Tk9TcWJSdWFmdkg4OTlldS02RjdlRlFsQUd4YS1RRlVkdFRVbVFMRVF2alVSMA?oc=5","date":"2024-07-23","type":"pipeline","source":"theguardian.com","summary":"HIV drug could be made for just $40 a year for every patient - theguardian.com","headline":"HIV drug could be made for just $40 a year for every patient","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE8wSXBUSEstYVBac1N2c0hsUlp6cTE1cjlBelZLQVprSlZ6S0xha1R5TUVMbzNwLU41ZGlBa3Rud28yR3dfVDlwa2FGWHR3R1R2Wnh5Q2JjcHNrVjNOeGx2NXM1NE4wVWpwWkZOMWhHenQyUDBC?oc=5","date":"2021-11-30","type":"pipeline","source":"PharmaTimes","summary":"GSK aim for HIV cure by 2030 - PharmaTimes","headline":"GSK aim for HIV cure by 2030","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOMlNwMzA5ZWlZaW1wSzBmdkM2c2RfSXlyM20yNVNCODRkS3g1SkxFQ2EybEhfWm54Zl91N0tuOVRUb3BFaHdhNDZDRW1pcURON2w2blZvZDJaOVYtcWlCMWlmaDgxeVAwdi15YUJ4Rld5NHA1dFN1aW11MEIxcTRXaURhYUtvUGNtRGVqa09iTEp6bTBEbFlOdkI1clYwdTAtUGdaNUdZQTdwVWZ4Wkl0cjZUenRDb1E?oc=5","date":"2016-03-23","type":"pipeline","source":"NPR","summary":"Drug Company Jacks Up Cost Of Aid-In-Dying Medication - NPR","headline":"Drug Company Jacks Up Cost Of Aid-In-Dying Medication","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNd2NQd3JGc25PTzByTksyWE9fS3hfcFhrV3V5TXlyVFJ0UFJkWWFWT2NQLUktc1NWNkYwUlpJcnZ4UXpyaVAyQWRfazVxcjhDOGc0VUVFeWs2dG9BZjJyNnJudkJyZXBkU1FlR0Q4bFZlZ0NTN3c2Tkg1dlc1UjRyT1UzT29CYnZleGxnS1BIblNESEVKTm44cWt0TDY4TXlFeWlrMHV0RlYxclZ1ZjM2MFUzOXVmT25u?oc=5","date":"2016-02-10","type":"patent","source":"MSF Access","summary":"Pharma company Viiv’s attempt to secure patents for key HIV drugs dolutegravir and cabotegravir opposed in India - MSF Access","headline":"Pharma company Viiv’s attempt to secure patents for key HIV drugs dolutegravir and cabotegravir opposed in India","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}